This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.

Inclusion Criteria:

• Inclusion criteria:

  • Established diagnosis of epilepsy that requires treatment with anti-seizure medication.
  • No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.
  • Diagnosis of ADHD with functional impairment.
  • Good general health as determined by medical history and physical examination, including stable vital signs.
  • Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.

Exclusion Criteria:

• • Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®

  • Active substance abuse or dependence within 30 days of enrollment
  • Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months
  • DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
  • Current use of stimulants to treat ADHD
  • Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
  • Unstable cardiac illness such as arrythmias or cardiomyopathy.
  • Participation in a previous experimental drug study within 30 days of baseline visit.
  • Estimated IQ<70 as indicated by clinical assessment to the degree that rating scales may be invalid
  • Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures

This is a small dataset so will not share IPD in order to preserve confidentiality.

open label, flexible dose